Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

BACKGROUND: Limited evidence-based therapies exist for the management of heart failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in patients with systolic heart failure (HFrEF) and type-2-diabetes mellitus (T2DM) is associated with improved cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Weijia, Katamreddy, Adarsh, Kataria, Rachna, Myerson, Merle L., Taub, Cynthia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844327/
https://www.ncbi.nlm.nih.gov/pubmed/34478119
http://dx.doi.org/10.1007/s40801-021-00277-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844327/
https://www.ncbi.nlm.nih.gov/pubmed/34478119
http://dx.doi.org/10.1007/s40801-021-00277-0

Ejemplares similares